Opinion 25 Jul 2022 How to improve patient recruitment in your precision medicine research …genetic test results for their children and other family members (46.4 percent). With dozens of precision medicine trials in specific forms of Parkinson’s and Alzheimer’s disease on the horizon, competition… July 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 …South Korean metropolis Daejeon, Orum Therapeutics focuses on a protein degrader approach, particularly in the ubiquitin-proteasome system, which is notably a potential therapeutic target according to research conducted for Alzheimer’s… March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 WhiteLab Genomics raises $10M for AI-powered genomic therapies platform …4,000 human diseases including Alzheimer’s disease, Parkinson’s disease, cystic fibrosis, cardiovascular disease, Duchenne muscular dystrophy, and some types of cancer, originate from errors and changes in an individual’s DNA sequence…. September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2021 The Top European Biotech Funding Rounds in July …the development of treatments for neurodegenerative conditions including Alzheimer’s disease. Meanwhile, a Series B round from Swedish firm Anocca made a big splash in Europe’s previously quiet TCR cell therapy… August 10, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2024 2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year …of the most prominent FDA approvals in the field that paved the way for further triumphs in the industry last year, was that of Leqembi for the treatment of Alzheimer’s… January 18, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2022 Get to know 15 of the best biotech companies in Paris …Alzheimer’s disease, which has completed phase 2a trials, and the rare condition amyotrophic lateral sclerosis, which is entering phase 2a. Tissium Tissium, previously known as Gecko Biomedical, has developed a… November 4, 2022 - 11 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Interview 28 Nov 2018 Navigating the Rare Disease Space: Insights from a Danish CEO …one of the most successful recent IPOs in European biotech. Even though the more common diseases such as Alzheimer’s disease, cardiovascular disease and cancer represent big markets, developing treatments for… November 28, 2018 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2025 Deal after deal: Novartis spends billions in 2025 …neurology having signed a licensing agreement with Swedish neurodrug developer BioArctic, famed for creating the once-hyped Alzheimer’s disease medicine Leqembi. The research collaboration will see the two combine the big pharma’s proposed undisclosed antibody with BioArctic’s platform technology BrainTransporter designed to allow antibodies… October 22, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe …therapeutic antibodies for series diseases including cancer, arthritis and Alzheimer’s. Today, the company has announced that the licensee, Janssen, has received approval from the European Commission for its psoriasis treatment,… November 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2021 European Biotechs Fire up Deals to Develop Parkinson’s Treatments …Ray Dorsey, Director of the Center for Health and Technology at the University of Rochester in Michigan, US. “Parkinson’s disease is the world’s fastest-growing brain disease, even faster than Alzheimer’s…. August 12, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Oct 2020 Top 10 Companies Combining AI and Drug Discovery in Europe …its name in 2016. BenevolentAI is working in a variety of disease areas including Alzheimer’s and ALS. While the company is working on its own drug candidates, it also has… October 19, 2020 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2022 Precision medicine research must lose its Eurocentricity …the here and now. Polygenic risk scores (PRS), which give an estimate of an individual’s liability to common and complex traits or disease like coronary artery disease, Alzheimer’s disease, or… October 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email